Log in

NASDAQ:EIDX - Eidos Therapeutics Stock Price, Forecast & News

$63.50
-2.07 (-3.16 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$62.04
Now: $63.50
$66.30
50-Day Range
$40.25
MA: $51.55
$65.57
52-Week Range
$11.15
Now: $63.50
$66.30
Volume392,031 shs
Average Volume226,954 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.86
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.22 per share

Profitability

Net Income$-33,290,000.00

Miscellaneous

Employees28
Market Cap$2.38 billion
Next Earnings Date4/20/2020 (Estimated)
OptionableNot Optionable

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.


Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) released its earnings results on Thursday, October, 31st. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.48. The business earned $26.69 million during the quarter. View Eidos Therapeutics' Earnings History.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 20th 2020. View Earnings Estimates for Eidos Therapeutics.

What price target have analysts set for EIDX?

6 analysts have issued 12-month price targets for Eidos Therapeutics' stock. Their forecasts range from $29.00 to $75.00. On average, they anticipate Eidos Therapeutics' stock price to reach $52.00 in the next year. This suggests that the stock has a possible downside of 18.1%. View Analyst Price Targets for Eidos Therapeutics.

What is the consensus analysts' recommendation for Eidos Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

Press coverage about EIDX stock has trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eidos Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Eidos Therapeutics.

Are investors shorting Eidos Therapeutics?

Eidos Therapeutics saw a drop in short interest in November. As of November 29th, there was short interest totalling 2,670,000 shares, a drop of 8.2% from the November 14th total of 2,910,000 shares. Based on an average daily trading volume, of 194,500 shares, the short-interest ratio is presently 13.7 days. Currently, 33.3% of the company's stock are sold short. View Eidos Therapeutics' Current Options Chain.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Roku (ROKU), Crispr Therapeutics (CRSP), DexCom (DXCM), Global Blood Therapeutics (GBT), Micron Technology (MU), bluebird bio (BLUE), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Intellia Therapeutics (NTLA).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the folowing people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Chief Bus. Officer (Age 29)
  • Dr. Hoyoung Huh, Consultant (Age 50)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (2.46%), State Street Corp (0.58%), Point72 Asset Management L.P. (0.44%), Alps Advisors Inc. (0.20%), SG Americas Securities LLC (0.11%) and Barclays PLC (0.09%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Jonathan C Fox, Neil Kumar, Rajeev M Shah and Uma Sinha. View Institutional Ownership Trends for Eidos Therapeutics.

Which institutional investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc. and Metropolitan Life Insurance Co NY. Company insiders that have sold Eidos Therapeutics company stock in the last year include Cameron Turtle, Christine Siu, Jonathan C Fox and Uma Sinha. View Insider Buying and Selling for Eidos Therapeutics.

Which institutional investors are buying Eidos Therapeutics stock?

EIDX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, SG Americas Securities LLC, California Public Employees Retirement System, Squarepoint Ops LLC, Barclays PLC, State Street Corp and California State Teachers Retirement System. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Eric Aguiar, Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $63.50.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $2.38 billion. The company earns $-33,290,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.View Additional Information About Eidos Therapeutics.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is http://www.eidostx.com/.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel